Autor según el artículo: Arenas, M; Fargas-Saladié, M; Moreno-Solé, M; Moyano-Femenia, L; Jiménez-Franco, A; Canela-Capdevila, M; Castañé, H; Martínez-Navidad, C; Camps, J; Joven, J
Departamento: Medicina i Cirurgia
Autor/es de la URV: Arenas Prat, Meritxell / Camps Andreu, Jorge / Castañé Vilafranca, Helena / Jiménez Franco, Andrea / Joven Maried, Jorge
Palabras clave: Therapeutic targets Neoadjuvant therapy Metabolomics Chemotherapy Breast cancer Biomarkers women therapeutic targets survival recurrence neoadjuvant therapy metabolomics management breast cancer
Resumen: Background: Triple-negative breast cancer stands out as the most aggressive subtype of breast malignancy and is characterized by an unfavourable prognosis. Objective: This systematic review summarizes the insights gleaned from metabolomic analyses of individuals afflicted with this cancer variant. The overarching goal was to delineate the molecular alterations associated with triple-negative breast cancer, pinpointing potential therapeutic targets and novel biomarkers. Methods: We systematically searched for evidence using the PubMed database and followed the PRISMA and STARLITE guidelines. The search parameters were delimited to articles published within the last 13 years. Results: From an initial pool of 148 scrutinized articles, 17 studies involving 1686 participants were deemed eligible for inclusion. The current body of research shows a paucity of studies, and the available evidence presents conflicting outcomes. Notwithstanding, Pathway Enrichment Analysis identified the urea and glucose-alanine cycles as the most affected metabolic pathways, followed by arginine, proline, and aspartate metabolism. Conclusion: Future investigations need to focus on elucidating which of those metabolites and/or pathways might be reliable candidates for novel therapeutic interventions or reliable biomarkers for diagnosis and prognosis of this subtype of breast cancer.
Áreas temáticas: Multidisciplinary sciences Multidisciplinary Medicina i Ciências biológicas ii Ciências biológicas i Biotecnología
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: andrea.jimenez@urv.cat jorge.camps@urv.cat jorge.joven@urv.cat meritxell.arenas@urv.cat helena.castane@estudiants.urv.cat
Identificador del autor: 0000-0002-3165-3640 0000-0003-2749-4541 0000-0003-0815-2570
Fecha de alta del registro: 2024-02-24
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.cell.com/heliyon/fulltext/S2405-8440(23)10836-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS240584402310836X%3Fshowall%3Dtrue#%20
Referencia al articulo segun fuente origial: Heliyon. 10 (1): e23628-
Referencia de l'ítem segons les normes APA: Arenas, M; Fargas-Saladié, M; Moreno-Solé, M; Moyano-Femenia, L; Jiménez-Franco, A; Canela-Capdevila, M; Castañé, H; Martínez-Navidad, C; Camps, J; Jo (2024). Metabolomics and triple-negative breast cancer: A systematic review. Heliyon, 10(1), e23628-. DOI: 10.1016/j.heliyon.2023.e23628
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI del artículo: 10.1016/j.heliyon.2023.e23628
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2024
Tipo de publicación: Journal Publications